Xtoro approved for swimmer's ear
18 December 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

The infection of the outer ear and ear canal, most often caused by ear canal bacteria, has typical symptoms including pain, swelling, redness and discharge, the FDA said in a news release.

The drug's safety and effectiveness were evaluated in a clinical study of more than 1,200 people, aged 6 months to 85 years. The most common side effects were ear itching and nausea.

Xtoro is produced by Alcon Laboratories, based in Fort Worth, Texas.

More information: The FDA has more about this approval.

Copyright © 2014 HealthDay. All rights reserved.

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.